Sanofi (NASDAQ:SNY) Downgraded by StockNews.com to Buy

Sanofi (NASDAQ:SNY) was downgraded by StockNews.com from a “strong-buy” rating to a “buy” rating in a research report issued to clients and investors on Monday.

A number of other brokerages have also commented on SNY. Citigroup raised shares of Sanofi to a “strong-buy” rating in a research report on Tuesday, September 17th. Argus boosted their price target on Sanofi from $55.00 to $60.00 and gave the stock a “buy” rating in a research report on Friday, July 26th. Three research analysts have rated the stock with a hold rating, two have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $57.50.

Sanofi Stock Performance

NASDAQ SNY opened at $54.96 on Monday. The business’s 50 day moving average price is $55.81 and its 200-day moving average price is $51.35. Sanofi has a fifty-two week low of $42.63 and a fifty-two week high of $58.97. The company has a market cap of $139.46 billion, a P/E ratio of 29.87, a P/E/G ratio of 1.56 and a beta of 0.60. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.65 and a current ratio of 1.00.

Sanofi (NASDAQ:SNY) last posted its quarterly earnings data on Thursday, July 25th. The company reported $0.93 earnings per share for the quarter, beating analysts’ consensus estimates of $0.88 by $0.05. The business had revenue of $10.75 billion for the quarter, compared to analysts’ expectations of $16.86 billion. Sanofi had a net margin of 9.60% and a return on equity of 26.29%. The business’s revenue was up 7.8% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.95 earnings per share. Sell-side analysts predict that Sanofi will post 4.25 earnings per share for the current year.

Institutional Trading of Sanofi

Institutional investors have recently made changes to their positions in the business. Boston Partners boosted its stake in Sanofi by 0.3% in the 1st quarter. Boston Partners now owns 13,066,403 shares of the company’s stock worth $635,280,000 after purchasing an additional 33,657 shares in the last quarter. Bank of New York Mellon Corp lifted its stake in shares of Sanofi by 19.0% during the second quarter. Bank of New York Mellon Corp now owns 8,594,740 shares of the company’s stock worth $417,017,000 after buying an additional 1,370,232 shares during the period. Barrow Hanley Mewhinney & Strauss LLC grew its holdings in shares of Sanofi by 113.8% during the second quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 5,943,547 shares of the company’s stock valued at $288,381,000 after buying an additional 3,164,092 shares during the last quarter. Mondrian Investment Partners LTD raised its stake in Sanofi by 43.1% in the 1st quarter. Mondrian Investment Partners LTD now owns 3,951,089 shares of the company’s stock worth $192,023,000 after acquiring an additional 1,190,141 shares during the last quarter. Finally, Envestnet Asset Management Inc. lifted its position in Sanofi by 8.2% during the 2nd quarter. Envestnet Asset Management Inc. now owns 3,252,326 shares of the company’s stock worth $157,803,000 after acquiring an additional 246,224 shares during the period. Institutional investors and hedge funds own 10.04% of the company’s stock.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.